COTA and Aetion partner to expand access to real-world data for oncology research

At the heart of every oncology breakthrough is trustworthy data.  Researchers rely on access to complete, accurate, timely, longitudinal information about cancer patients to observe the impacts of new therapies in clinical trials and make decisions about what to recommend for individuals with cancer in the community.

But getting access to enough high-quality real-world data (RWD) hasn’t always been easy for life science companies and their research partners.  It can be time-consuming, challenging, and expensive to develop datasets on one’s own, especially without established experience in the space.

That’s why COTA has partnered with Aetion®, a global leader in real-world evidence (RWE) and analytics, to make it faster and easier to access fit-for-purpose datasets for research.  By combining the power of the Aetion Evidence Platform® (AEP) with COTA’s clinically curated, multi-source oncology Vantage RWD assets, investigators will be able to streamline access to meaningful data so they can focus on the science instead.

This collaboration enables Aetion and COTA to meet the needs of researchers requiring high-quality, clinically rich oncology data, for both liquid and solid tumor types. COTA’s newly expanded Vantage datasets in multiple myeloma (MM), non-small cell lung cancer (NSCLC), and acute myeloid leukemia (AML) are now available for use on AEP, in addition to other cancer-specific datasets from COTA.

"COTA and Aetion are a natural fit for collaboration, since we are both driven to accelerate oncology research through the use of regulatory grade real-world data and real-world evidence. Making COTA’s oncology data available through the Aetion Evidence Platform will enhance the utility of both our offerings. We are excited to deepen our relationship with Aetion and continue to knock down barriers to better treatments for cancer patients."
“We are delighted to partner with COTA to give researchers the opportunity to uncover new and rapid insights to accelerate treatment options and more effectively care for patients with unmet medical needs."

COTA is already an active member of the Aetion CARE Initiative, a cross-industry, cross-functional initiative to better understand the role of RWD and RWE in emulating trials for evaluating oncology therapeutics.

The CARE team is working on designing emulated clinical trials using RWD and RWE with less restrictive inclusion/exclusion criteria than standard randomized controlled trials.  The goal is to balance scientific rigor with inclusiveness and representation when developing cancer drugs that must be safe and effective for a wide variety of patients in real-world clinical settings.

Their findings will inform the next generation of cancer research and provide further proof points that RWD and RWE have a critical role to play in the future of clinical trials.

“Clinical trial data can be limited in scope and external validity. RWD and RWE not only contain numerous essential elements for oncology trials, but additional insights that can only be gained by thinking outside the traditional sources of research data. Our goal is to make sure that the entire oncology research community understands the value of RWD and can access the most comprehensive and appropriate datasets for their needs. Working with Aetion on the CARE Initiative, as well as our new innovative data partnership, will help us all accomplish our shared goals: to bring safer, more effective, more affordable treatments to people experiencing cancer faster.”

To learn more about COTA’s RWD capabilities visit cotahealthcare.com.